238 related articles for article (PubMed ID: 12586204)
1. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
2. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
Popik P; Krawczyk M; Golembiowska K; Nowak G; Janowsky A; Skolnick P; Lippa A; Basile AS
Cell Mol Neurobiol; 2006; 26(4-6):857-73. PubMed ID: 16636898
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
[TBL] [Abstract][Full Text] [Related]
6. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
[TBL] [Abstract][Full Text] [Related]
7. "Broad spectrum" antidepressants: is more better for the treatment of depression?
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Life Sci; 2003 Nov; 73(25):3175-9. PubMed ID: 14561522
[TBL] [Abstract][Full Text] [Related]
8. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and transporter binding properties of 3beta-[4'-(phenylalkyl, -phenylalkenyl, and -phenylalkynyl)phenyl]tropane-2beta-carboxylic acid methyl esters: evidence of a remote phenyl binding domain on the dopamine transporter.
Blough BE; Keverline KI; Nie Z; Navarro H; Kuhar MJ; Carroll FI
J Med Chem; 2002 Aug; 45(18):4029-37. PubMed ID: 12190324
[TBL] [Abstract][Full Text] [Related]
11. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.
Tizzano JP; Stribling DS; Perez-Tilve D; Strack A; Frassetto A; Chen RZ; Fong TM; Shearman L; Krieter PA; Tschöp MH; Skolnick P; Basile AS
J Pharmacol Exp Ther; 2008 Mar; 324(3):1111-26. PubMed ID: 18089843
[TBL] [Abstract][Full Text] [Related]
12. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
13. Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines.
Okada T; Fujita M; Shimada S; Sato K; Schloss P; Watanabe Y; Itoh Y; Tohyama M; Nishimura T
Nucl Med Biol; 1998 Jan; 25(1):53-8. PubMed ID: 9466362
[TBL] [Abstract][Full Text] [Related]
14. Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate.
Rothman RB; Silverthorn ML; Baumann MH; Goodman CB; Cadet JL; Matecka D; Rice KC; Carroll FI; Wang JB; Uhl GR
J Pharmacol Exp Ther; 1995 Jul; 274(1):385-95. PubMed ID: 7616423
[TBL] [Abstract][Full Text] [Related]
15. Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.
Hoepping A; Johnson KM; George C; Flippen-Anderson J; Kozikowski AP
J Med Chem; 2000 May; 43(10):2064-71. PubMed ID: 10821718
[TBL] [Abstract][Full Text] [Related]
16. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Prins J; Denys DA; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Groenink L; Olivier B; Korte SM
Eur J Pharmacol; 2010 May; 633(1-3):55-61. PubMed ID: 20153745
[TBL] [Abstract][Full Text] [Related]
17. Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse.
Sørensen G; Husum H; Brennum LT; Bundgaard C; Montezinho LC; Mørk A; Wörtwein G; Woldbye DP
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):451-9. PubMed ID: 24314270
[TBL] [Abstract][Full Text] [Related]
18. Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55.
Rothman RB; Cadet JL; Akunne HC; Silverthorn ML; Baumann MH; Carroll FI; Rice KC; de Costa BR; Partilla JS; Wang JB
J Pharmacol Exp Ther; 1994 Jul; 270(1):296-309. PubMed ID: 8035327
[TBL] [Abstract][Full Text] [Related]
19. Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.
Kolhatkar R; Cook CD; Ghorai SK; Deschamps J; Beardsley PM; Reith ME; Dutta AK
J Med Chem; 2004 Oct; 47(21):5101-13. PubMed ID: 15456254
[TBL] [Abstract][Full Text] [Related]
20. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
